pregnancy or breast-feeding
Item
nonpregnant, nonlactating females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
HCG test
Item
females of child bearing potential must have a negative human chorionic gonadotropin (hcg) test result within 60 days before the first dose of study material.
boolean
C0546577 (UMLS CUI [1])
contraceptive methods
Item
males and females must practice adequate contraception, in the judgement of the investigator, during the course of the study.
boolean
C0700589 (UMLS CUI [1])
relapsing remitting multiple sclerosis
Item
subjects must have a diagnosis of clinically definite relapsing remitting multiple sclerosis based on medical history, physical examination, laboratory test results, and neurologic examination. alternatively, subjects may have clinically probable ms characterized by 1 attack and the presence of at least 4 lesions on mri within 12 months before the initial baseline evaluation.
boolean
C0751967 (UMLS CUI [1])
EDSS
Item
subjects must have an expanded disability status scale (edss) test result of less than or equal to 5.0 within 60 days before the first dose of study material.
boolean
C0451246 (UMLS CUI [1])
serum uric acid level
Item
subjects will have serum uric acid levels less than 5 mg/dl.
boolean
C0041980 (UMLS CUI [1,1])
C0229671 (UMLS CUI [1,2])
clinical relapse
Item
have 1 clinical relapse in the last year
boolean
C0856120 (UMLS CUI [1])
comorbidity
Item
presence of any medical disability or laboratory test result that, in the judgement of the investigator, would interfere with assessment of the tolerability, safety, or efficacy of study material or would compromise the subject's ability to provide informed consent.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2])
evidence of active infection
Item
evidence of active infection characterized by requiring treatment with antibiotics within 7 days before the first dose of study material.
boolean
C0009450 (UMLS CUI [1])
treatment
Item
treatment with interferons, glatiramer acetate, lymphoid irradiation, cyclophosphamide, or with other immune modifying treatments within 3 months, or corticosteroids within 1 month before the initial baseline mri assessment in this trial.
boolean
C0021747 (UMLS CUI [1])
C0289884 (UMLS CUI [2])
C0024230 (UMLS CUI [3])
C0010583 (UMLS CUI [4])
drug or alcohol abuse
Item
recent history (within the previous 2 years) of drug or alcohol abuse.
boolean
C0038586 (UMLS CUI [1])
allergy to inosine
Item
known allergy to inosine products or history of anaphylaxis.
boolean
C0020517 (UMLS CUI [1,1])
C0021528 (UMLS CUI [1,2])
C0002792 (UMLS CUI [2])
previous randomization
Item
previous randomization into this study.
boolean
C0034656 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
treatment with an investigational agent
Item
treatment with an investigational agent within 30 days before the first dose of study material.
boolean
C2348568 (UMLS CUI [1])